Anti-ERBB2 (Trastuzumab)-vandetanib ADC

Business Offer

United States

https://www.creative-biolabs.com/adc/target-erbb2-37.htm This ADC product is comprised of an anti-ERBB2 monoclonal antibody (Trastuzumab) conjugated via a linker to vandetanib . The maytansine is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell,maytansine binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death. Vandetanib (trade name Caprelsa) is an anti-cancer drug.It acts as a kinase inhibitor of a number of cell receptors, mainly the vascular endothelial growth factor receptor (VEGFR), the epidermal growth factor receptor (EGFR), and the RET-tyrosine kinase

https://www.creative-biolabs.com/adc/target-erbb2-37.htm This ADC product is comprised of an anti-ERBB2 monoclonal antibody (Trastuzumab) conjugated via a linker to vandetanib . The maytansine is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell,maytansine binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death. Vandetanib (trade name Caprelsa) is an anti-cancer drug.It acts as a kinase inhibitor of a number of cell receptors, mainly the vascular endothelial growth factor receptor (VEGFR), the epidermal growth factor receptor (EGFR), and the RET-tyrosine kinase

[RequestAdvantages]

[RequestComments]

919

Creative Biolabs